Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATOS
ATOS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATOS News
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer
4d ago
PRnewswire
Atossa Presents Robust ER Inhibition Data for (Z)-Endoxifen in Breast Cancer
4d ago
Newsfilter
Atossa's New Research Findings on DMD Treatment
May 20 2026
Newsfilter
Atossa's New Research Findings on DMD
May 20 2026
PRnewswire
Atossa Hosts Key Opinion Leader Event on (Z)-Endoxifen
May 14 2026
PRnewswire
Atossa Therapeutics Q1 Financial Results
May 08 2026
seekingalpha
Atossa Therapeutics Reports Q1 2026 Financial Results and Updates
May 08 2026
PRnewswire
Atossa Announces KARISMA Trial Results for Endoxifen in Breast Cancer Prevention
May 06 2026
PRnewswire
Atossa Reports Positive Results from Endoxifen Clinical Trial for Breast Cancer Risk Reduction
May 06 2026
Newsfilter
Atossa's Drug Receives Rare Pediatric Disease Designation
May 04 2026
stocktwits
Atossa Secures Rare Pediatric Disease Designation for (Z)-endoxifen
May 04 2026
PRnewswire
Atossa Secures Rare Pediatric Disease Designation for (Z)-endoxifen
May 04 2026
Newsfilter
Atossa Therapeutics Reports FY Losses
Mar 26 2026
seekingalpha
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Mar 25 2026
stocktwits
Atossa Therapeutics Reports 2025 Financial Results and Updates
Mar 25 2026
PRnewswire
Atossa Therapeutics Reports 2025 Financial Results and Corporate Developments
Mar 25 2026
Newsfilter
Show More News
